Zimmer Biomet Holdings (ZBH) Announces Board Changes

Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including:

• Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;
  
• President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; and
  
• Michael Farrell will become Lead Independent Director upon Mr. Begley's retirement.

Retirement of Mr. Begley

"Chris has been a tremendous advisor to Zimmer Biomet since joining the Board in 2012. His vision, thoughtful counsel, and dedication to the Company have been instrumental in positioning Zimmer Biomet as a MedTech leader and innovator," said Mr. Tornos. "On behalf of the entire Board of Directors and Leadership Team, I want to extend my deep gratitude to Chris for his exemplary leadership and service as a member of Zimmer Biomet's Board. We have all benefited immensely from Chris's guidance, leadership and mentorship as Board Chair."

Mr. Begley has been a member of the Company's Board of Directors since 2012, has served as Non-Executive Chairman since August 2023 and prior to that served as Lead Independent Director since May 2021. During his tenure as a Director, he has also served as a member of the Corporate Governance and the Compensation and Management Development Committees, and as Chair of the Quality, Regulatory and Technology Committee. He is the retired Chairman and Chief Executive Officer of Hospira, Inc. and the retired Non-Executive Chairman of the Board of Hanger, Inc.

Appointment of Mr. Tornos as Chairman of the Board

"Ivan has demonstrated bold leadership during his tenure as President and CEO, and prior to that as Chief Operating Officer, at Zimmer Biomet," said Mr. Begley. "I and the entire Board of Directors are excited to see how he continues to drive even stronger value for patients, shareholders, physicians and customers in his expanded role as Chairman of the Board."

Appointment of Mr. Farrell as Lead Independent Director

Mr. Farrell has been a Zimmer Biomet Board member since 2014 and currently serves as Chairman of the Compensation and Management Development Committee and as a member of the Quality, Regulatory and Technology Committee. He is the Chairman and Chief Executive Officer of ResMed Inc. Mr. Tornos stated, "We are honored to have Mick serve as our Lead Independent Director. He is a respected and accomplished business leader who brings strong integrity, a collaborative approach, and a valuable strategic perspective to our Board. I look forward to working with him in his new role."

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Home Depot expands executive roles, grants $500K in restricted stock
• Lazard Global Total Return fund declares $0.1534 monthly distribution